Privigen immunoglobulin intravenous (human)

Privigen is indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in patients 15 years of age and older, chronic inflammatory demyelinating polyneuropathy in adults.

Pearl of the day medication: Privigen immunoglobulin intravenous (human)

Indication: Privigen is an immunoglobulin intravenous (human), 10% liquid indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in patients 15 years of age and older, chronic inflammatory demyelinating polyneuropathy in adults.

Insight:

  • Dosage: The dosage can vary from 0.5 mg/kg/min to 8 mg/kg/min
  • Dosage forms: Privigen is a liquid solution containing 10% IgG (0.1 g/mL).
  • Adverse events: The most common adverse reactions, observed in >5% of study subjects, were headache, fatigue, nausea, chills, vomiting, back pain, pain, blood pressure increased, body temperature, abdominal pain, diarrhea, cough, stomach discomfort, chest pain, joint swelling. /effusion, flu syndrome, pharyngolaryngeal pain, hives and dizziness. Serious adverse effects were hypersensitivity, chills, fatigue, dizziness and increased body temperature.
  • Action mechanism: Privigen provides a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents. The mechanism of action has not been fully elucidated but may include immunomodulatory effects.

Source: Privigen-Prescribe-Information.pdf (llnwd.net)

Comments are closed.